Dr. Templin is a board-certified toxicologist with more than 15 years of experience in preclinical and early clinical drug development. He has extensive experience in small molecules, biologics, peptides and multiple classes of nucleic acid-based drugs, and has worked in multiple therapeutic areas including cancer, inflammation, cardiovascular, metabolic and antivirals. He also has experience with nonhuman primate programs, including design, oversight and interpretation of research and GLP studies for INDs, NDAs and ex-U.S. submissions.
“This is an exciting time for SNBL USA and our clients,” said Mark Crane, vice president of business development. “Dr. Templin’s exceptional preclinical and early clinical background, along with his technical expertise and outstanding communication skills, will significantly enhance the benefits in working with SNBL USA.